CD79A and infection: Ninety percent of all infections occur in mucosal surfaces lining the gastrointestinal, respiratory and urogenital tracts, where the first line of defense is secretory IgA (sIgA) [31]; however, parenteral vaccines are largely limited to targeting pathogens that have already breached the mucosal barrier, via serum IgG [32].